Congress Alerts

Release Date December 15, 2011

Expiration Date December 15, 2012

This expert interview with Craig Langman, MD, from Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States, and Laurence Greenbaum, MD, PhD, from Emory University, Atlanta, Georgia, United States, along with an eNewsflash and slides, covers the topic of atypical hemolytic uremic syndrome (aHUS), focusing on the following data releases:

Abstract 193: Eculizumab is an effective long-term treatment in patients with atypical hemolytic uremic syndrome resistant to plasma exchange/infusion: Results of an extension study

After successful completion of this continuing medical education activity, participants should be able to:

• Describe current treatment strategies and guidelines for patients with aHUS
• Evaluate recent clinical trial data regarding the safety and efficacy of novel therapies in the management of patients with aHUS, including incorporation of targeted agents into treatment approaches

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME^®) to provide continuing medical education for physicians.



prIME Oncology designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online post test and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you.

A link to the post test is available on the video player page.

Disclosure of Conflicts of Interest
prIME Oncology assesses conflicts of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Faculty Disclosures

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Dr Greenbaum has disclosed that he has received fees as a consultant for Alexion. He has received other fees (non-CME services) from Alexion. He has also performed contracted research for Alexion. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Langman has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

 

The employees of prIME Oncology have disclosed:

• Chelsey Goins, PhD (clinical) – no relevant financial relationships to disclose
• Trudy Stoddert, ELS (editorial) – no relevant financial relationships to disclose
• Susan H Yarbrough, CCMEP (compliance) – no relevant financial relationships to disclose

Disclosure of Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.